• Richter investor presentation set out 2035 strategy focused on pharmaceuticals, targeting global growth with emphasis on women’s healthcare and mental health.
• Sales revenue totaled EUR 2.3 billion in 2025 across four business units; women’s healthcare delivered global revenue of EUR 826 million.
• Women’s healthcare positioned as expected largest cEBIT contributor by 2035, with plan to double revenue and expand beyond contraception into areas such as PCOS and women’s oncology.
• Neuropsychiatry strategy centered on maximizing cariprazine value ahead of patent cliff, with aim to launch next original molecule; Vraylar ranked 21st best-selling small molecule drug in US in 2024.
• Biotech plans included reaching biosimilar breakeven via four new biosimilar launches while scaling CDMO business; GenMed roadmap targeted expansion in Western Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gedeon Richter plc published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.